Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects

Merel Jacobs, Hannelore P. Van Eeckhoutte, Sara R.A. Wijnant, Wim Janssens, Guy F. Joos, Guy G. Brusselle, Ken R. Bracke
European Respiratory Journal 2020 56: 2002378; DOI: 10.1183/13993003.02378-2020
Merel Jacobs
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Merel Jacobs
Hannelore P. Van Eeckhoutte
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara R.A. Wijnant
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
2Dept of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
3Dept of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sara R.A. Wijnant
Wim Janssens
4Respiratory Division and Rehabilitation, University Hospital Leuven, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wim Janssens
Guy F. Joos
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guy F. Joos
Guy G. Brusselle
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
2Dept of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
5Dept of Respiratory Diseases, Erasmus Medical Center, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guy G. Brusselle
Ken R. Bracke
1Laboratory for Translational Research in Obstructive Pulmonary Diseases, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ken.bracke@UGent.be
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

This study demonstrates increased protein levels of ACE2 in alveolar and bronchial epithelium of smokers and subjects with COPD, which might facilitate host cell entry of SARS-CoV-2 https://bit.ly/2ZazOrd

To the Editor:

Angiotensin-converting enzyme 2 (ACE2) has been identified as the cell entry receptor used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. Importantly, smokers and patients with COPD are at an increased risk of severe complications and a higher mortality upon SARS-CoV-2 infection [3]. We hypothesised that ACE2 expression is increased in lungs of smokers and patients with COPD, which may at least partially explain their higher risk of a more severe course of coronavirus disease 2019 (COVID-19). Therefore, we aimed to investigate the expression of ACE2 on both mRNA and protein level in a large number of lung tissue specimens of well-phenotyped subjects, including never-smokers, current smokers without airflow limitation, and patients with COPD.

In this cross-sectional observational study, we analysed lung tissue specimens from 134 subjects from our large lung tissue biobank at Ghent University Hospital (Ghent, Belgium) and from explant lungs from end-stage COPD patients collected at UZ Gasthuisberg Leuven (Leuven, Belgium). Ex-smoking was defined as smoking cessation for ≥1 year. COPD severity was defined according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification. Written informed consent was obtained from all subjects, and the study was approved by the medical ethical committees of Ghent University Hospital (2016/0132; 2019/0537) and the University Hospital Gasthuisberg Leuven (S51577).

RNA extraction from lung tissue blocks of 120 subjects was performed with the miRNeasy Mini kit (Qiagen, Hilden, Germany). Next, cDNA was prepared with the EvoScript Universal cDNA Master Kit (Roche, Basel, Switzerland), followed by reverse transcriptase (RT)-qPCR analysis for ACE2 and 3 reference genes, as described previously [4, 5].

Sections from formalin-fixed paraffin-embedded lung tissue blocks of 87 subjects were stained for ACE2. After antigen retrieval with citrate buffer (Scytek, West Logan, UT, USA), the slides were incubated with anti-ACE2 antibody (polyclonal rabbit-anti-human, Abcam ab15248). Next, slides were coloured with diaminobenzidine (Dako, Carpinteria, CA, USA) and counterstained with Mayer's haematoxylin (Sigma-Aldrich, St Louis, MO, USA). Quantitative measurements of the ACE2-positive signal in alveolar tissue and bronchial epithelium were performed on images of stained paraffin sections as described previously [6].

Statistical analysis was performed using Sigma Stat software (SPSS 26.0, Chicago, IL, USA) and R3.5.1, using Kruskal–Wallis tests (on all six groups) followed by Mann–Whitney U-tests (for the comparison between two groups), and multivariable linear regression analyses.

Using RT-PCR, ACE2 mRNA levels were determined in lung tissue from 120 subjects. ACE2 mRNA expression was significantly higher in the lung tissue of current smokers without airflow limitation and current smokers with COPD (GOLD stages II and III–IV) compared with never-smokers (figure 1a). In addition, ex-smokers without airflow limitation showed significantly lower ACE2 mRNA levels, compared with current smokers. Multivariable linear regression analysis demonstrated that current smoking and COPD are both independently associated with increased ACE2 mRNA expression in lung tissue, even after adjustment for covariates, including age, sex, body mass index and arterial hypertension (data not shown).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Gene and protein expression of angiotensin-converting enzyme 2 (ACE2) in the airways and lungs. a) ACE2 mRNA expression is increased in the lung tissue of smokers and COPD subjects. ACE2 mRNA expression in the lung tissue of never-, current and ex-smokers without airflow limitation and current and ex-smokers with moderate (Global Initiative of Chronic Obstructive Lung Disease (GOLD) stage II) or severe-to-very severe (GOLD stage III–IV) COPD, normalised to the expression of the housekeeping controls glyceraldehyde-3-phosphate dehydrogenase, peptidylprolyl isomerase A and succinate dehydrogenase complex flavoprotein subunit A. b) ACE2 protein levels are increased in the alveolar tissue of smokers and COPD subjects. Representative images and quantification of ACE2 immunohistochemical staining in the alveolar tissue of never-smokers, smokers without airflow limitation, smokers with COPD GOLD stage II and smokers with COPD GOLD stage III–IV. The area of ACE2-positive signal was normalised to the total area of alveolar tissue present in each analysed image. c) ACE2 protein levels are increased in the bronchial epithelium of smokers and COPD subjects. Representative images and quantification of ACE2 immunohistochemical staining in the bronchial epithelium of never-smokers, smokers without airflow limitation and smokers with COPD (GOLD stages II and III–IV). The area of ACE2-positive signal in each airway was normalised to the length of the basement membrane (Pbm). Data are presented as means±sem. *: p<0.05; **: p<0.01; ***: p<0.001.

Through immunohistochemical (IHC) staining, ACE2 protein levels were assessed in lung tissue from 87 subjects. ACE2 IHC revealed positive staining in both bronchial and alveolar epithelial cells, with the latter predominantly in alveolar type II cells (figure 1b and c). Quantification of ACE2 protein levels in the alveolar tissue revealed a significantly higher percentage of ACE2-positive alveolar tissue in current smokers without airflow limitation and current smokers with COPD (GOLD stages II and III–IV) compared with never-smokers (figure 1b). Moreover, the percentage of ACE2-positive alveolar tissue was significantly higher in patients with COPD GOLD stage III–IV, compared with ex-smokers without airflow limitation and ex-smokers with COPD GOLD stage II (figure 1b). Quantification of ACE2 staining in the bronchial epithelium revealed numerically higher levels in current smokers without airflow limitation and current smokers with COPD GOLD stage II, and significantly higher levels in patients with COPD GOLD stage III–IV, compared with never-smokers (figure 1c). Moreover, ACE2 protein levels in the bronchial epithelium were significantly higher in patients with COPD GOLD stage III–IV, compared with ex-smokers without airflow limitation and ex-smokers with COPD GOLD stage II (figure 1c). The observed association between COPD and ACE2 protein expression in alveolar tissue or bronchial epithelium remained significant after adjustment for possible confounders (data not shown).

As healthcare systems around the world are currently under great pressure due to the COVID-19 outbreak, identification of those at high risk is crucial. There is compelling evidence of a more severe course of COVID-19 in smokers and patients with comorbidities such as COPD. We clearly demonstrate an increased pulmonary expression of the SARS-CoV-2 entry receptor ACE2 in smokers and COPD subjects at both mRNA and protein level. While our observations complement previous reports on increased ACE2 mRNA and protein levels in whole lung tissue and bronchial epithelium [7–10], this is the first study demonstrating increased ACE2 protein in the alveolar epithelium of smokers and patients with COPD, which can be directly linked to the site of injury when patients with severe COVID-19 develop dyspnoea, hypoxia and pneumonia.

Currently, published data on COVID-19 in patients with COPD is fairly limited [11]. Nevertheless, an increased risk of developing severe COVID-19 as well as a higher mortality, has been reported in patients with COPD and in current smokers [3, 12]. Although there are several possible explanations for the increased susceptibility of severe COVID-19 in patients with COPD, including older age, comorbidities, dysregulated immune defences and impaired mucociliary clearance, increased pulmonary expression of the SARS-CoV-2 entry receptor ACE2 is most likely another contributor [13]. Importantly, it has been demonstrated in mouse models that transgenic (over)expression of human ACE2 enhances the pathogenicity of SARS-CoV-1 and SARS-CoV-2 [14]. Moreover, human ACE2 was essential for viral replication in the lung.

The main strength of this study is the large number of lung tissue samples from well-phenotyped subjects that are included in the RT-PCR and IHC analyses. Moreover, IHC allowed us to quantify ACE2 protein levels in both bronchial and alveolar epithelium. However, certain limitations should be kept in mind. First, this study consists mainly of samples from lung resections for pulmonary tumours. This may introduce selection bias, as altered expression of ACE2 in lung cancer has been suggested [15]. Secondly, samples of (very) severe COPD originate from a different patient population (lung transplantation), for which smoking cessation was an inclusion criterium. Finally, as we did not study lung tissue samples from COVID-19-positive subjects, we can only speculate on the importance of increased ACE2 in the pathogenicity of SARS-CoV-2.

In conclusion, we report higher ACE2 mRNA and protein levels in lung tissue of smokers and subjects with moderate-to-(very)-severe COPD. Importantly, ACE2 protein levels are not only increased in bronchial but also in alveolar epithelium. Further research is needed to elucidate whether upregulation of ACE2 expression in airways and lungs has consequences for the infectivity and clinical outcome of COVID-19.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-02378-2020.Shareable

Footnotes

  • Conflict of interest: M. Jacobs has nothing to disclose.

  • Conflict of interest: H.P. Van Eeckhoutte has nothing to disclose.

  • Conflict of interest: S.R.A. Wijnant has nothing to disclose.

  • Conflict of interest: G.F. Joos reports grants from AstraZeneca and Chiesi, personal fees for consultancy from Bayer and Eureca vzw, grants and personal fees for lectures and consultancy from GlaxoSmithKline, personal fees for lectures from Teva, outside the submitted work; all fees were paid to the department.

  • Conflict of interest: W. Janssens reports grants from AstraZeneca and Chiesi.

  • Conflict of interest: G.G. Brusselle reports personal fees for advisory board work and lectures from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva, personal fees for advisory board work from Sanofi, outside the submitted work.

  • Conflict of interest: K.R. Bracke has nothing to disclose.

  • Support statement: The research described in this article was supported by the Concerted Research Action of the Ghent University (BOF/GOA 01G00819) and by the Fund for Scientific Research in Flanders (FWO Vlaanderen, G052518N and EOS-contract G0G2318N). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received May 26, 2020.
  • Accepted June 19, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Xu X,
    2. Chen P,
    3. Wang J, et al.
    Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 63: 457–460. doi:10.1007/s11427-020-1637-5
    OpenUrlCrossRefPubMed
  2. ↵
    1. Zhou P,
    2. Yang XL,
    3. Wang XG, et al.
    A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270–273. doi:10.1038/s41586-020-2012-7
    OpenUrlCrossRefPubMed
  3. ↵
    1. Alqahtani JS,
    2. Oyelade T,
    3. Aldhahir AM, et al.
    Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One 2020; 15: e0233147. doi:10.1371/journal.pone.0233147
    OpenUrl
  4. ↵
    1. Seys LJ,
    2. Verhamme FM,
    3. Schinwald A, et al.
    Role of B cell-activating factor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 192: 706–718. doi:10.1164/rccm.201501-0103OC
    OpenUrlCrossRefPubMed
  5. ↵
    1. Conickx G,
    2. Mestdagh P,
    3. Avila Cobos F, et al.
    MicroRNA profiling reveals a role for microRNA-218-5p in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 195: 43–56. doi:10.1164/rccm.201506-1182OC
    OpenUrl
  6. ↵
    1. Seys LJM,
    2. Widagdo W,
    3. Verhamme FM, et al.
    DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. Clin Infect Dis 2018; 66: 45–53. doi:10.1093/cid/cix741
    OpenUrlCrossRef
  7. ↵
    1. Leung JM,
    2. Yang CX,
    3. Tam A, et al.
    ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55: 2000688.
    OpenUrlAbstract/FREE Full Text
    1. Cai G,
    2. Bossé Y,
    3. Xiao F, et al.
    Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med 2020; 201: 1557–1559.
    OpenUrlPubMed
    1. Milne S,
    2. Yang CX,
    3. Timens W, et al.
    SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors. Lancet Respir Med 2020; 8: e50–e51. doi:10.1016/S2213-2600(20)30224-1
    OpenUrl
  8. ↵
    1. Zhang H,
    2. Rostami MR,
    3. Leopold PL, et al.
    Expression of the SARS-CoV-2 ACE2 receptor in the human airway epithelium. Am J Respir Crit Care Med 2020; 202: 219–229.
    OpenUrl
  9. ↵
    1. Tal-Singer R,
    2. Crapo JD
    . COPD at the time of COVID-19: a COPD foundation perspective. Chronic Obstr Pulm Dis 2020; 7: 73–75.
    OpenUrl
  10. ↵
    1. Zhao Q,
    2. Meng M,
    3. Kumar R, et al.
    The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol 2020; in press [https://doi.org/10.1002/jmv.25889].
  11. ↵
    1. Lan J,
    2. Ge J,
    3. Yu J, et al.
    Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581: 215–220.
    OpenUrl
  12. ↵
    1. Bao L,
    2. Deng W,
    3. Huang B, et al.
    The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020; 583: 830–833.
    OpenUrl
  13. ↵
    1. Chai P,
    2. Yu J,
    3. Ge S, et al.
    Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. J Hematol Oncol 2020; 13: 43. doi:10.1186/s13045-020-00883-5
    OpenUrlPubMed
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 2 Table of Contents
European Respiratory Journal: 56 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects
Merel Jacobs, Hannelore P. Van Eeckhoutte, Sara R.A. Wijnant, Wim Janssens, Guy F. Joos, Guy G. Brusselle, Ken R. Bracke
European Respiratory Journal Aug 2020, 56 (2) 2002378; DOI: 10.1183/13993003.02378-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects
Merel Jacobs, Hannelore P. Van Eeckhoutte, Sara R.A. Wijnant, Wim Janssens, Guy F. Joos, Guy G. Brusselle, Ken R. Bracke
European Respiratory Journal Aug 2020, 56 (2) 2002378; DOI: 10.1183/13993003.02378-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
  • Balancing the risks and benefits of in-circuit bacterial filters
  • Polyurethane foam degradation in CPAP devices for sleep apnoea
Show more Agora

Research letters

  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
  • Polyurethane foam degradation in CPAP devices for sleep apnoea
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society